Contact Information: Contact information: John Gorman Email Contact: 480-385-3800
Health Enhancement Products Reports Results in Testing of the ProAlgaZyme Clinical Lot Used in the Suspended Clinical Trial
Clinical Materials That Had Ice Particles Showed Loss of Active Components, Compared to the Original Product
| Source: Health Enhancement Products, Inc.
SCOTTSDALE, AZ--(Marketwire - October 25, 2007) - Health Enhancement Products, Inc. (OTCBB : HEPI ) announced today that they have received preliminary, independent
results of the clinical lot of ProAlgaZyme that was used in the recently
suspended clinical trial. The test was designed to detect potential
degradation of the active protein components in ProAlgaZyme. Dr. Michael
Tempesta, who has been appointed as Chairman of the Scientific Advisory
Board and has worked with HEPI for several years stated: "The original
clinical product, which had not been frozen, was tested and showed the
presence of active protein. However, in the same tests, all the returned
clinical samples that had been frozen showed clear signs of loss of active
protein. This is an indication that the frozen product received for the
trials was rendered inactive, and would not be expected to produce a
measurable effect on the patients." Dr. Tempesta also stated that,
"Additional tests are underway, and the results will be announced once they
are completed. New labeling will now include a warning to not freeze the
product."
About Health Enhancement Products, Inc. and ProAlgaZyme
Health Enhancement Products, Inc. is a nutraceutical company engaged in the
development of a Dietary Supplement product using only pure, all-natural
ingredients. The company's sole product is ProAlgaZyme, a liquid product
produced from algae grown in 100% distilled water. The liquid in which the
algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme.
HEPI Pharmaceuticals, Inc. is exploring the development of the potential
pharmaceutical applications of ProAlgaZyme.
Except for any historical information, the matters discussed in this press
release contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These forward-looking statements involve risks and
uncertainties. A number of factors could cause actual results to differ
from those indicated in the forward-looking statements, including the
timing of completion of a trial, actual future clinical trial results being
different than the results the company has obtained to date, our inability
to obtain regulatory approvals necessary to market and sell PAZ as a
pharmaceutical, and the company's ability to secure funding, including for
the subsidiary's pharmaceutical development of PAZ. Such statements are
subject to a number of assumptions, risks and uncertainties. Readers are
cautioned that such statements are not guarantees of future performance and
that actual results or developments may differ materially from those set
forth in the forward-looking statements. The company undertakes no
obligation to publicly update or revise forward-looking statements, whether
as a result of new information or otherwise.
For more information, please visit www.heponline.com.